Janssen 54767414 MMY3021 “Auriga”
A Randomized Study of Daratumumab plus Lenalidomide vs. Lenalidomide Alone vs Maintenance Treatment in Patients with Newly Diagnosed Mulitple Myeloma Who Are Minimal Residual Disease Positive after Frontline Autologous Stem Cell Transplant.
Janssen 54767414 MMY2065 “Lynx”
A Phase 2 Study Comparing Daratumumab Subcutaneous Administration in Combination with Carfilzomib, and Dexamethasone (DKd) vs Carfilzomib and Dexamethasone (Kd) in Subjects with Multiple Myeloma who have been Previously treated with Daratumumab IV.
©2019 Fort Wayne Medical Oncology and Hematology. All Rights Reserved.